Author
Senior reporter
Covid-19: Big pharma to the rescue
As the world watches and waits for a vaccine, we ask what IR is like under the pandemic spotlight
‘The scrutiny is extraordinarily high,’ says Nick Mazing, director of research at Sentieo, talking about the media and market focus on pharmaceuticals and biotech firms involved in the fight against Covid-19. ‘And it’s not just scrutiny. It is interference.’
As
Content Preview
to continue reading
Subscribe
- IR Essentials - print editions
- Unlimited Articles online
- Newsletter
- Award Winning IR reports
- Strategy guides
- White papers
from$995*
Case studies
– The DealBook newsletter from The New York Times focused on the political ‘entanglements’ of the NYSE and parent company Intercontinental...Read more
On October 19, the Canadian IR community logged in to join the first ever virtual IR Magazine Awards – Canada. Hundreds of people tuned into the...Read more
From introducing your new CFO virtually to completing a merger almost a year later than expected (and in the midst of a global pandemic) or working...Read more
In the year that IR truly went virtual, it was only fitting that the IR Magazine Awards – Europe did the same. In October we held our first virtual...Read more
